共 61 条
[1]
Johnson JA(2011)Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing Clin Pharmacol Ther 90 625-629
[2]
Gong L(2012)Prediction of warfarin dose: why, when and how? Pharmacogenomics 13 429-440
[3]
Whirl-Carrillo M(2013)Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model PLoS ONE 8 e71505-496
[4]
Eriksson N(2010)Pharmacogenetics of coumarinic oral anticoagulants Pharmacogenomics 11 493-453
[5]
Wadelius M(2011)Population diversity and the performance of warfarin dosing algorithms Br J Clin Pharmacol 72 451-603
[6]
Mazzaccara C(2002)Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population Br J Clin Pharmacol 53 596-135
[7]
Conti V(2011)Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients Pharmacogenet Genomics 21 130-524
[8]
Liguori R(2012)Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen Int J Lab Hematol 34 517-6105
[9]
Manolopoulos VG(2010)In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes Blood 116 6101-521
[10]
Ragia G(2002)Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population Br J Clin Pharmacol 54 518-1116